The field of oncology has witnessed significant advancements over the past decades, with targeted therapy emerging as a promising strategy to combat cancer. This approach focuses on the molecular and genetic alterations that drive cancer progression, offering the potential for more personalized and effective treatments.
Targeted therapy works by interfering with specific proteins or processes that support the growth and survival of cancer cells. Unlike traditional chemotherapy, which indiscriminately attacks all rapidly dividing cells, targeted therapies are designed to affect only cancer cells, thereby reducing collateral damage to healthy tissues.
Targeted therapies can be broadly categorized into small molecules and monoclonal antibodies. Small molecules, like tyrosine kinase inhibitors, can penetrate the cell membrane and interfere with the function of proteins inside the cell. Monoclonal antibodies, on the other hand, are too large to enter cells. Instead, they target proteins on the cell surface or the surrounding environment.
Targeted therapy has the potential to be more effective and less toxic than traditional chemotherapy. However, its effectiveness can be limited by factors such as tumor heterogeneity and drug resistance. Furthermore, the identification of appropriate targets requires detailed molecular profiling of the tumor, which can be challenging and time-consuming.
Despite these challenges, the future of targeted therapy in oncology is promising. Advances in genomics and proteomics are likely to identify new targets for therapy. Additionally, the development of combination therapies and strategies to overcome drug resistance are active areas of research.
In conclusion, targeted therapy represents a significant shift in the treatment of cancer. While challenges remain, the potential benefits of this approach, including improved efficacy and reduced toxicity, make it a compelling area of study for the future of oncology.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation